EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review

Sheila Recarey-Rama iD, Jesús Gómez-Trigo, Almudena Gil-Rodriguez iD, Eduardo Dominguez iD, Inés Sánchez-Martínez, Ángela Riveiro-Recimil, Alba Barral-Raña, Jose de Leon iD, Ana Rodriguez-Viyuela, Manuel Arrojo, Angel Carracedo iD, Olalla Maroñas

Pharmaceuticals · 25.04.2025 · 18 (5) · 623

DOI: 10.3390/ph18050623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 25.04.2025. Verfasst von Sheila Recarey-Rama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782 Santiago …. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Instituto de Salud Carlos III (ISCIII) and co-funded with European Union funds., Instituto de Salud Carlos III (ISCIII), European Union funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Methadone maintenance treatment (MMT) is widely used in opioid use disorder (OUD). Its efficacy is influenced by its metabolism, primarily mediated by Cytochrome P450 (CYP450) enzymes in the liver. Genetic polymorphisms in CYP450 genes and other factors, such as age, sex, and concomitant treatments, contribute to interindividual variability in methadone response. This article addresses the relevance of pharmacokinetic biomarkers in methadone metabolism and its impact on treatment outcomes in European populations over the past 25 years.

Methods

A systematic review was conducted using four databases (PsycINFO, PubMed, Scopus, and Web of Science) for studies published between 2000 and 2024 following the PRISMA 2020 guidelines (CRD42025641373 in PROSPERO). Two independent reviewers screened and assessed the study quality using NHLBI tools. Discrepancies were solved through consensus. Relevant data including sample size, genetic biomarkers, and key findings were extracted for each study. Data were synthesized and described in detail.

Results

Fourteen studies on pharmacogenetic biomarkers influencing methadone metabolism in European populations were analyzed, encompassing a total of 3180 subjects. CYP2B6*6 was identified as a key variant associated with increased (S)-methadone plasma levels, potentially leading to cardiac complications, while the role of other pharmacokinetic genes, including ABCB1 and CYP2D6, was inconclusive.

Conclusions

Genetic polymorphisms significantly influence methadone metabolism, with the CYP2B6*6 allele playing a key role in (S)-methadone metabolism and associated with cardiac risks. Pharmacogenetic studies integrating co-mediation—the principal cause of phenoconversion—as a potential variable alongside gender differences and encompassing adequate sample sizes could improve outcomes and establish the basis for personalized medicine of MMT.

Schlagwörter

Stichwörter der Autor:innen

biomarkersgenesmaintenance therapiesmetabolismmethadoneopioid addictionpharmacogenetics

Autor:innen und Institutionen

  • Genomic Medicine Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Pharmacogenomics and Drug Discovery Group (GenDeM), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Psychiatry Service, University Hospital Complex of Santiago de Compostela, Galician Health System (SERGAS), 15706 Santiago de Compostela, Spain.
  • Faculty of Pharmacy, University of Santiago de Compostela, 15705 Santiago de Compostela, Spain.
  • Genetics Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Mental Health Research Center at Eastern State Hospital, University of Kentucky, Lexington, KY 40511, USA.

ORCID-Profile: Sheila Recarey-Rama, Almudena Gil-Rodriguez, Eduardo Dominguez, Jose de Leon, Angel Carracedo

Förderung

  • This study was funded by Instituto de Salud Carlos III (ISCIII) and co-funded with European Union funds.
  • Instituto de Salud Carlos III (ISCIII)
  • European Union funds

Zitieren

APA

Recarey-Rama, S., Gómez-Trigo, J., Gil-Rodriguez, A., Dominguez, E., Sánchez-Martínez, I., Riveiro-Recimil, Á., Barral-Raña, A., de Leon, J., Rodriguez-Viyuela, A., Arrojo, M., Carracedo, A., & Maroñas, O. (2025). The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review. Pharmaceuticals, 18(5), 623. https://doi.org/10.3390/ph18050623

Vancouver

Recarey-Rama S, Gómez-Trigo J, Gil-Rodriguez A, Dominguez E, Sánchez-Martínez I, Riveiro-Recimil Á, et al. The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review. Pharmaceuticals. 2025;18(5):623. doi:10.3390/ph18050623

BibTeX
@article{RecareyRama2025,
  author = {Recarey-Rama, Sheila and Gómez-Trigo, Jesús and Gil-Rodriguez, Almudena and Dominguez, Eduardo and Sánchez-Martínez, Inés and Riveiro-Recimil, Ángela and Barral-Raña, Alba and de Leon, Jose and Rodriguez-Viyuela, Ana and Arrojo, Manuel and Carracedo, Angel and Maroñas, Olalla},
  title = {The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {5},
  pages = {623},
  doi = {10.3390/ph18050623}
}
Kostenlos starten →